Amprion Secures More Capital to Advance Novel Neurologic Diagnostics to Market nextdigitalhealth.com
A global biotechnology company focused on developing diagnoses for neurodegenerative disorders, Amprion, has secured $6 million in the initial close of its $15 million series B funding round.
According to the company’s announcement last week, the initial phase of the funding round was spearheaded by Formation Venture Engineering (FVE), with significant contributions from Eli Lilly and Company, alongside its Series A investors.
Report Story
3 Comments
This research was funded by the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Grants ZIA DK 075057, ZIA DK 075062, and ZIA DK 075063 priligy canada
Link exchange is nothing else except it is only placing the other person’s web site link on your page at appropriate place and other person will
also do same for you.
Krintel JJ, Haxholdt OS, Berthelsen P, Brockner J Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis cost of cytotec price The anastrozole patients also had fewer diagnoses of endometrial cancer, thromboembolic and cerebrovascular events, and hot flashes